Embecta Grows with Owen Mumford Acquisition | Business and Finance News

Embecta’s Q3 earnings show mixed but promising signs, with U.S. business rebounding and international growth holding strong. The acquisition of Owen Mumford is a major win, expanding their portfolio into pharmaceutical services and auto-injectors — especially the versatile Aidaptus platform — tapping into a $2.4B+ market. New leadership in Pharma Services signals serious commitment to this expansion. Despite U.S. headwinds, Embecta’s cost controls are boosting margins and EPS, and they’re reaffirming full-year guidance while actively paying down debt — positioning them for smarter, broader growth. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/efd83f16935b656c